Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The high incidence and poor prognosis of heart failure (HF) patients affected with diabetes (DM) is in part related to a specific cardiac remodeling currently recognized as diabetic cardiomyopathy (DCM). This cardiac frame occurs regardless of the presence of coronary artery diseases (CAD) and it can account for 15–20% of the total diabetic population. The pathogenesis of DCM remains controversial, and several molecular and cellular alterations including myocardial hypertrophy, interstitial fibrosis, oxidative stress and vascular inflammation, have been postulated. The main cardio-vascular alterations associated with hyperglycemia comprise endothelial dysfunction, adverse effects of circulating free fatty acids (FFA) and increased systemic inflammation. High glucose concentrations lead to a loss of mitochondrial networks, increased reactive oxygen species (ROS), endothelial nitric oxide synthase (eNOS) activation and a reduction in cGMP production related to protein kinase G (PKG) activity. Current mechanisms enhance the collagen deposition with subsequent increased myocardial stiffness. Several concerns regarding the exact role of DCM in HF development such as having an appearance as either dilated or as a concentric phenotype and whether diabetes could be considered a causal factor or a comorbidity in HF, remain to be clarified. In this review, we sought to explain the different DCM subtypes and the underlying pathophysiological mechanisms. Therefore, the traditional and new molecular and signal alterations and their relationship with macroscopic structural abnormalities are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261 · cited 1×
“Advanced glycation end products—AGEs are proteins or lipids that become glycated after exposure to sugars, which alters their functional properties [48].”
BackgroundA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“Nevertheless, the ORIGIN trial including 12,000 patients did not demonstrate significant differences in terms of HF episodes between subjects submitted to insulin glargine and controls [31].”
MicroRNA-34a regulates cardiac ageing and function.
Boon, R. A., Iekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., Kaluza, D., Tréguer, K., Carmona, G., Bonauer, A., et al. (2013) · Nature · doi:10.1038/nature11919 · Cited by 821 · cited 1×
“miR-1 [69,75] Downregulated Hypertrophy and oxidative stress Cardiac and skeletal muscle miR-1/206 [71] Upregulated Cardiomyocytes apoptosis Cardiac muscle miR-34a [71,74] Upregulated Cardiomyocytes apoptosis Cardiac muscle miR-133a [69] Downregulated Hypertrophy and oxidative stress Cardiac and skeletal muscle miR-19…”
BackgroundThe Incidence of Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Gullion, C. M., Koro, C. E., Ephross, S. A., & Brown, J. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1879 · Cited by 812 · cited 1×
“A recent population-based cohort registry demonstrated that diabetes is the primary driver for combined end point of myocardial infarction (MI) and HF [3,4].”
BackgroundSeferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708 · cited 3×
“NTproBNP and high sensitivity troponin T, respectively biomarkers of myocardial wall stress and cardiomyocyte injury, showed a higher accuracy in recognizing HFrEF patients with eccentric LV remodeling [1,10,79,80].”
BackgroundMacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · cited 2×
“The highest prevalence of DM was registered in trials of acute HF (around 40%) [9].”
BackgroundThe miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., et al. (2012) · Nature Communications · doi:10.1038/ncomms2090 · Cited by 610 · cited 1×
“miR-1 [69,75] Downregulated Hypertrophy and oxidative stress Cardiac and skeletal muscle miR-1/206 [71] Upregulated Cardiomyocytes apoptosis Cardiac muscle miR-34a [71,74] Upregulated Cardiomyocytes apoptosis Cardiac muscle miR-133a [69] Downregulated Hypertrophy and oxidative stress Cardiac and skeletal muscle miR-19…”
BackgroundCongestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Hillier, T. A., Erbey, J. R., & Brown, J. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1614 · Cited by 600
Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus
Shenouda, S. M., Widlansky, M. E., Chen, K., Xu, G., Holbrook, M., Tabit, C. E., Hamburg, N. M., Frame, A. A., Caiano, T. L., Kluge, M. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.014506 · Cited by 570
Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L. (2015) · Circulation · doi:10.1161/circulationaha.114.014796 · Cited by 501 · cited 1×
“Diabetes is also associated with an elevated risk of hospitalization ~33% [11].”
BackgroundAnderson, E. J., Kypson, A. P., Rodriguez, E., Anderson, C. A., Lehr, E. J., & Neufer, P. D. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.031 · Cited by 440
Nguyen, M. T. A., Satoh, H., Favelyukis, S., Babendure, J. L., Imamura, T., Sbodio, J. I., Zalevsky, J., Dahiyat, B. I., Chi, N.-W., & Olefsky, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504611200 · Cited by 411 · cited 1×
“Increased oxidative stress is associated with the stimulation of various serine/threonine kinases c-Jun NH2-terminal kinase (JNK), PKCs, and IκB kinase complex β (IKK β) [58,59].”
BackgroundImpact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401 · cited 1×
“These data underline the importance of cumulative glycemic burden, rather than glycemic control at a given point in time [7,8].”
BackgroundHemmingsen, B., Lund, S. S., Gluud, C., Vaag, A., Almdal, T., Hemmingsen, C., & Wetterslev, J. (2011) · BMJ · doi:10.1136/bmj.d6898 · Cited by 386 · cited 1×
“important HF risk factor related to outcome in DM patients is a higher value of glycosylated hemoglobin (HbA1c), although a strict glycemic control is not associated with a substantial decrease in CV events [6].”
BackgroundKristensen, S. L., Preiss, D., Jhund, P. S., Squire, I., Cardoso, J. S., Merkely, B., Martinez, F., Starling, R. C., Desai, A. S., Lefkowitz, M. P., et al. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002560 · Cited by 359
Heart Failure With Preserved Ejection Fraction and Diabetes
McHugh, K., DeVore, A. D., Wu, J., Matsouaka, R. A., Fonarow, G. C., Heidenreich, P. A., Yancy, C. W., Green, J. B., Altman, N., & Hernandez, A. F. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.033 · Cited by 313
Sarma, S., Mentz, R. J., Kwasny, M. J., Fought, A. J., Huffman, M., Subacius, H., Nodari, S., Konstam, M., Swedberg, K., Maggioni, A. P., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs153 · Cited by 202 · cited 1×
“31) after adjusting for confounding factors [18].”
Kristensen, S. L., Mogensen, U. M., Jhund, P. S., Petrie, M. C., Preiss, D., Win, S., Køber, L., McKelvie, R. S., Zile, M. R., Anand, I. S., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024593 · Cited by 202
Li, S.-Y., Yang, X., Ceylan-Isik, A. F., Du, M., Sreejayan, N., & Ren, J. (2006) · Diabetologia · doi:10.1007/s00125-006-0229-0 · Cited by 187 · cited 1×
“All these features, translated into a human model, could hypothesize a specific role of Ca2+ overload in contractile dysfunction and in impaired relaxation in DCM [64,65].”
BackgroundTargher, G., Dauriz, M., Laroche, C., Temporelli, P. L., Hassanein, M., Seferovic, P. M., Drozdz, J., Ferrari, R., Anker, S., Coats, A., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.679 · Cited by 169 · cited 1×
“5-fold and 3-fold increased risk for in-hospital and long-term mortality respectively, when compared with non-diabetics [5].”
BackgroundDauriz, M., Mantovani, A., Bonapace, S., Verlato, G., Zoppini, G., Bonora, E., & Targher, G. (2017) · Diabetes Care · doi:10.2337/dc17-0697 · Cited by 123
Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study
Elder, D. H. J., Singh, J. S. S., Levin, D., Donnelly, L. A., Choy, A.-M., George, J., Struthers, A. D., Doney, A. S. F., & Lang, C. C. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.455 · Cited by 109
Myocardial Infarction Triggers Chronic Cardiac Autoimmunity in Type 1 Diabetes
Gottumukkala, R. V. S. R. K., Lv, H., Cornivelli, L., Wagers, A. J., Kwong, R. Y., Bronson, R., Stewart, G. C., Schulze, P. C., Chutkow, W., Wolpert, H. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003551 · Cited by 76
Dauriz, M., Targher, G., Temporelli, P. L., Lucci, D., Gonzini, L., Nicolosi, G. L., Marchioli, R., Tognoni, G., Latini, R., Cosmi, F., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005156 · Cited by 70 · cited 1×
“event rates were similar between non-DM patients and pre-DM patients [17].”
Result
Cited by
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
Metadata
- Authors
- Evangelista, I., Nuti, R., Picchioni, T., Dotta, F., & Palazzuoli, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-07-02
- Volume
- 20
- Issue
- 13
- Pages
- 3264
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2954531847
- Cited by
- 165
- References
- 27
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.